Back to homepage

Tag "Diabetes mellitus"

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus

Authors: Constantine E Kosmas MD, PhD, Delia Silverio MD, Andreas Sourlas, Frank Garcia MD, Peter D Montan MD, Eliscer Guzman MD

This review aims to present and discuss the clinical and scientific data pertaining to the impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.

More

Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus

Authors: Richard Brice, Sharon Shelley, Pankaj Chaturvedi, Divina Glah, Donna Ashley, Monica Hadi

Management of type 2 diabetes mellitus (T2DM) often requires intervention with oral and injectable therapies. Across National Health Service (NHS) England, injectable therapies may be initiated in secondary, intermediate or primary care. This original research set out to understand resource utilization, the pathways of care, clinical outcomes, and experience of patients with T2DM
initiated on injectable therapies.

More

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin

Authors: Jeffrey Freeman

In this article the author discusses the implications for clinical practice of the results of a recent Phase III trial. He concludes that initial combination of linagliptin plus metformin which was found to be weight neutral, well tolerated and associated with a low frequency of hypoglycaemia, may have advantages for a large proportion of patients with type 2 diabetes, particularly those with a relatively high HbA1c at diagnosis.

More

Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes

Authors: Stanley S Schwartz

In this article the author argues that in type 2 diabetes, an approach that emphasizes diet and exercise and features a treatment regimen tailored to the needs of the individual to reach glycemic targets is warranted in most patients and provides microvascular and cardiovascular benefit, provided that hypoglycemia is avoided.

More

Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?

Authors: Eva Vivian, Chelsea Mannebach

In this article authors review recent studies and evaluate the benefits and risks of combination therapy with an angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB), or a direct renin inhibitor (DRI) to attenuate the progression of diabetic nephropathy.

More